No Summer Break? Legal, Enforcement Issues Tax Boston Scientific Counsel
This article was originally published in The Gray Sheet
Executive Summary
Manhattan federal court will determine whether Boston Scientific is entitled to payment from Medinol for lost revenue associated with the Nir Flex stent
You may also be interested in...
Boston Scientific stent patent prevails
U.S. District Court for Delaware June 15 upholds a 2005 jury determination that Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent infringes Boston Scientific's "Ding" patent for non-thrombogenic polymer technology. Cordis had asked the court to overturn the 2005 jury verdict and now says it will appeal the decision by District Court Judge Sue Robinson (1"The Gray Sheet" July 4, 2005, p. 5). The ruling is Robinson's third in six weeks on patent disputes between the sparring drug-eluting stent manufacturers. Prudential Equity Group senior medical device analyst Larry Biegelsen said in a June 15 research note that the continuing stent intellectual property battle between the two firms is "unlikely to have a substantial financial impact on either party"...
Boston Scientific stent patent prevails
U.S. District Court for Delaware June 15 upholds a 2005 jury determination that Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent infringes Boston Scientific's "Ding" patent for non-thrombogenic polymer technology. Cordis had asked the court to overturn the 2005 jury verdict and now says it will appeal the decision by District Court Judge Sue Robinson (1"The Gray Sheet" July 4, 2005, p. 5). The ruling is Robinson's third in six weeks on patent disputes between the sparring drug-eluting stent manufacturers. Prudential Equity Group senior medical device analyst Larry Biegelsen said in a June 15 research note that the continuing stent intellectual property battle between the two firms is "unlikely to have a substantial financial impact on either party"...
Following Win Over Boston Scientific, Medinol Seeks Taxus Liberté Royalties
Medinol says it will pursue royalties from sales of Boston Scientific's Taxus Liberté drug-eluting stent following a Sept. 21 settlement of the firms' long-running patent infringement suit